Limits...
Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions.

Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G - J. Exp. Clin. Cancer Res. (2008)

Bottom Line: These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in the glucose metabolism of melanocytic cells.Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas.Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Anatomic Pathology, Catholic University Sacro Cuore, Rome, Italy. paolaparenteanapat@yahoo.it

ABSTRACT

Background: Reported data indicate that cancer cells have increased rates of glucose metabolism, as determined by 18FDG-PET imaging in patients with malignancies. The results of many studies have demonstrated that the expression of glucose transporters, especially Glut-1, is increased in a variety of malignancies. This study was undertaken to assess the differential expression of Glut-1 and Glut-3 by benign and malignant melanocytic lesions.

Methods: Immunohistochemical staining for Glut-1 and Glut-3 was performed on paraffin-embedded tissue sections prepared from melanocytic nevi (12 cases), Spitz nevi (12 cases) and primary cutaneous malignant melanomas (20 cases).

Results: We observed immunoreactivity for Glut-1 in all melanocytic nevi, 9 of the 12 Spitz nevi and in 9 of the 20 malignant melanomas, whereas Glut-3 was expressed in all the melanocytic lesions, both benign and malignant.

Conclusion: These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in the glucose metabolism of melanocytic cells. Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas. Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.

Show MeSH

Related in: MedlinePlus

Glut-1 is not expressed in a malignant melanoma > 1 mm thick.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2553059&req=5

Figure 4: Glut-1 is not expressed in a malignant melanoma > 1 mm thick.

Mentions: Of the ten cases in the group with thickness > 1 mm, Glut-1 immunoreactivity was present in four tumours, with weak immunoreactivity in three cases and moderate immunoreactivity in one case. Six tumours did not show Glut-1 immunoreactivity [Figure 4]. Glut-3 expression was evident in all tumours, with intense immunoreactivity in nine cases [Figure 5] and weak immunoreactivity in one case. Four cases were positive for both Glut-1 and Glut-3.


Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions.

Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G - J. Exp. Clin. Cancer Res. (2008)

Glut-1 is not expressed in a malignant melanoma > 1 mm thick.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2553059&req=5

Figure 4: Glut-1 is not expressed in a malignant melanoma > 1 mm thick.
Mentions: Of the ten cases in the group with thickness > 1 mm, Glut-1 immunoreactivity was present in four tumours, with weak immunoreactivity in three cases and moderate immunoreactivity in one case. Six tumours did not show Glut-1 immunoreactivity [Figure 4]. Glut-3 expression was evident in all tumours, with intense immunoreactivity in nine cases [Figure 5] and weak immunoreactivity in one case. Four cases were positive for both Glut-1 and Glut-3.

Bottom Line: These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in the glucose metabolism of melanocytic cells.Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas.Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Anatomic Pathology, Catholic University Sacro Cuore, Rome, Italy. paolaparenteanapat@yahoo.it

ABSTRACT

Background: Reported data indicate that cancer cells have increased rates of glucose metabolism, as determined by 18FDG-PET imaging in patients with malignancies. The results of many studies have demonstrated that the expression of glucose transporters, especially Glut-1, is increased in a variety of malignancies. This study was undertaken to assess the differential expression of Glut-1 and Glut-3 by benign and malignant melanocytic lesions.

Methods: Immunohistochemical staining for Glut-1 and Glut-3 was performed on paraffin-embedded tissue sections prepared from melanocytic nevi (12 cases), Spitz nevi (12 cases) and primary cutaneous malignant melanomas (20 cases).

Results: We observed immunoreactivity for Glut-1 in all melanocytic nevi, 9 of the 12 Spitz nevi and in 9 of the 20 malignant melanomas, whereas Glut-3 was expressed in all the melanocytic lesions, both benign and malignant.

Conclusion: These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in the glucose metabolism of melanocytic cells. Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas. Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.

Show MeSH
Related in: MedlinePlus